PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Pediatr Res. Author manuscript; available in PMC 2010 June 1.
Published in final edited form as:
PMCID: PMC2780332
NIHMSID: NIHMS108690

Effects of dietary cholesterol and simvastatin on cholesterol synthesis in Smith-Lemli-Opitz syndrome (SLOS)

Abstract

Deficient cholesterol and/or excessive 7-dehydrocholesterol (7-DHC) may be responsible for the pathology of Smith-Lemli-Opitz syndrome (SLOS). Both high cholesterol diets given to ameliorate cholesterol deficiency while decreasing 7-DHC, and cholesterol-enriched diets plus simvastatin to further decrease sterol synthesis, have been used as potential therapies. However, the effect of dietary cholesterol and simvastatin on cholesterol synthesis in SLOS has not been reported. Twelve SLOS subjects enrolled in the study: Nine had received a high cholesterol diet (HI) for 3 years, and three were studied after 4 weeks on a low cholesterol diet (LO). Cholesterol fractional synthesis rate (FSR) was measured after oral administration of deuterium oxide, using gas-chromatography-isotope ratio mass spectrometry. FSR was lower in HI compared with LO (HI: 1.46±0.62%/d; LO: 4.77±0.95%/d; P<0.001). Three HI subjects were re-tested after 0.8 years taking simvastatin (HI+ST). Simvastatin tended to reduce FSR and significantly decreased (P<0.01) plasma 7-DHC compared to cholesterol supplementation alone. The study demonstrates the utility of the deuterium incorporation method to understand the effect of therapeutic interventions in SLOS. The data suggest that dietary cholesterol supplementation reduces cholesterol synthesis in SLOS and further support the rationale for the combined treatment of SLOS with a cholesterol-enriched diet and simvastatin.

Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder, which is characterized by multiple anomalies and mental retardation (1-5). Patients with SLOS typically exhibit low plasma cholesterol concentrations along with high concentrations of 7- dehydrocholesterol (7-DHC) (6) which is the immediate precursor of cholesterol, as well as its isomer, 8-dehydrocholesterol (8-DHC) (7). The abnormal cholesterol and non-cholesterol-sterol profiles in SLOS are present as a result of deficient activity of 7-dehydrocholesterol Δ7-reductase (DHCR7) (8) which converts 7-DHC to cholesterol in the last step of the cholesterol biosynthetic pathway. Since cholesterol deficiency and 7-DHC excess likely both contribute to the pathogenesis of SLOS, the therapeutic goal for the treatment of SLOS has been to enhance cholesterol accretion while decreasing accumulation of potentially toxic cholesterol precursors such as 7-DHC.

Cholesterol-enriched diets can ameliorate cholesterol deficiency in SLOS via cholesterol absorption from the diet. At the same time, synthesis of sterols including cholesterol and its precursors such as 7-DHC, is inhibited via feedback inhibition on hydroxymethylglutaryl Coenzyme A reductase (HMG CoA R) by cholesterol supplementation (4, 9). Therefore, dietary cholesterol supplementation has been the most commonly proposed potential treatment for SLOS (10-13). However, the effects of dietary cholesterol consumption on cholesterol synthesis in the SLOS population have not been widely studied. More recently, statins, HMG CoA R inhibitors, have been suggested as a potential treatment (14). Statins have been postulated to be beneficial in SLOS via reduction of 7-DHC synthesis by inhibiting HMG CoA R (14) and paradoxically increasing cholesterol synthesis by enhancing the residual activity of mutant DHCR7, as noted in in vitro human studies and in vivo animal studies (15, 16). Simvastatin has been chosen for SLOS studies because it can cross the blood brain barrier and potentially ameliorate the sterol derangements in both plasma and brain. Indeed, circulating 7-DHC and 8-DHC concentrations were observed to be reduced in SLOS subjects (14, 17) and increased cholesterol levels were obtained (14) as a result of simvastatin administration. Cerebrospinal fluid sterol ratios were improved as well (14). Since the use of simvastatin as potential treatment for SLOS yielded promising results in ameliorating sterol profiles in SLOS (14, 17), it is crucial to evaluate the effects of a high cholesterol diet, with and without simvastatin, on whole body cholesterol synthesis and circulating sterol levels in subjects with SLOS.

The objective of this study was, therefore, to evaluate cholesterol synthesis and sterol concentrations in SLOS to determine the effect of diet and simvastatin to help establish the optimal therapeutic strategy for SLOS.

Subjects and Methods

Subjects

Twelve subjects were recruited from the clinics at Oregon Health & Science University (OHSU) and from outside referrals to the OHSU SLOS research program. The OHSU Institutional Review Board approved these studies, and written informed consent was obtained in all cases. In addition to noting the presence of characteristic clinical features (5) diagnosis of patients with SLOS was confirmed by blood sterol analysis documenting diagnostic elevation of plasma 7-DHC, and/or documented mutations in DHCR7, the gene encoding the DHCR7 enzyme deficient in SLOS. Severity score was reported using a previously established scoring system (5, 18).

Experimental design, protocol and diets

The present study evaluated the effect of a high cholesterol diet on cholesterol synthesis relative to a low cholesterol diet, and the effects of simvastatin treatment combined with dietary cholesterol supplementation. Three subjects (4.4 to 11.3 y of age) were evaluated after consuming a low cholesterol diet (0.5 to 5 mg cholesterol/kg/d) for 4 wks (LO), and nine subjects (1.1 to 15.7 y of age) were evaluated while treated with a high cholesterol diet (HI; average treatment: 3 y). Three of the HI subjects (1.8 to 3 y of age) were reevaluated after treatment with the high cholesterol diet and simvastatin for approximately 0.8 y (HI+ST).

Food sources for infants or tube-fed children consisted of infant or pediatric formula. Toddlers and children who ate orally and were consuming the low cholesterol diet were fed regular table foods that were very low in cholesterol, such as fruits, vegetables, breads, soy products, and fat-free dairy products. During the high cholesterol diet period, dietary cholesterol was given either in a food-based or crystalline form. Food-based cholesterol was given at a mean of 34.5 mg/kg/d, whereas crystalline cholesterol was given at 47 mg/kg/d. Cholesterol-containing foods utilized in the study included egg yolk and other foods high in cholesterol including butter, cheese and meat. Egg yolk was incorporated into food in high cholesterol diet in a variety of ways. Dried or mashed hard-boiled egg yolk was added to formula, liquids, baby food, or solid foods. Raw egg yolks were cooked in an eggnog type drink, or raw pasteurized egg yolks were incorporated into beverages. In a few cases, subjects refused to eat eggs and were provided crystalline cholesterol. The crystalline cholesterol was suspended in a commercial aqueous emulsifier (OraPlus™) and was administered as medication.

Subjects were given simvastatin orally or via feeding tube. Parents of SLOS subjects were properly instructed in drug administration as well as in monitoring potential side effects prior to the initiation of simvastatin treatment. The dose of simvastatin was gradually increased from 0.2 mg/kg, to a maximum of 0.4 mg/kg, based on effects of the medication on plasma sterols in patients with SLOS.

Stable isotope administration protocol and blood sample processing

Subjects were admitted to the General Clinical Research Center (now the Pediatric Clinical and Translational Research Center of the Oregon Clinical and Translational Research Institute-NIH CTSA grant) at OHSU. A baseline blood sample (10 ml) was taken in the morning before breakfast was consumed. Then, deuterium oxide (D2O; 99.8 atom percent excess; CDN Isotopes, Montreal) was given at a dose of 500 mg/kg of body weight. A second blood sample (10 ml) was collected 24 h after D2O administration. Samples were centrifuged at 2000 rpm for 10 min to separate red blood cells (RBC) and plasma. Buffy coat was discarded and the red blood cells and plasma were immediately stored at -80°C until further analysis.

Subjects treated with simvastatin were monitored for potential adverse effect of the drug by measuring creatine kinase and transaminase serum concentration. Simvastatin treatment was discontinued if creatine kinase was above normal and/or serum transaminases were greater than three times the upper limit of normal.

Cholesterol fractional synthesis rate methodology

The rate of deuterium from body water incorporated into RBC membrane free cholesterol over 0 h to 24 h of each visit was taken as an indicator of cholesterol synthesis. Therefore, deuterium enrichments were measured in both RBCs and plasma water. The deuterium enrichment of free cholesterol extracted from RBCs was analyzed in samples obtained at 0 h and 24 h of each visit utilizing a gas chromatography/pyrolysis/isotope ratio mass spectrometry (GC/P/IRMS) approach. The free cholesterol was extracted from RBCs through the following procedures. Methanol was added to RBCs, and samples were heated at 55°C in a shaking water bath for 15 min, before addition of hexane:chloroform (4:1, by volume) and double-distilled water. Thereafter, samples were centrifuged for 15 min at 1500 rpm at 4°C. Supernatants of the samples were dried down under nitrogen and re-dissolved with hexanes and subsequently transferred in injection vials. Samples were injected into an Agilent 6890N gas chromatograph (GC). A 30-m capillary column (SAC-5; Supelco, Bellefonte, CA) was installed in the GC and programmed to separate the sterols: the starting temperature was 160°C and was increased by 15°C/min to 245°C and isothermal for 4 min; increased by 15°C/min to 280°C and isothermal for 4 min; increased by 25°C/min to 305°C and isothermal for 10 min; and returned to 160°C by 48°C/min. The GC was connected to a Delta V Plus isotope ratio mass spectrometer (IRMS) through pyrolysis furnace (alumina tubing, reactor temperature at 1450°C). Under these conditions, the organic hydrogen and deuterium from newly synthesized free cholesterol was converted to hydrogen and deuterium gas. The deuterium enrichment of this gas was then detected by the Delta V Plus IRMS system. Isotopic ratios were expressed as δ D/H in per mil against V-SMOW (Vienna Standard Mean Ocean Water). The deuterium enrichment of plasma water was measured using differential IRMS coupled with a manually operated dual-inlet system with electrical H3+ compensation (VG Isomass 930D) as reported previously (19). An aliquot of plasma water sample was analyzed by temperature conversion elemental analyzer (TC/EA)-IRMS. After correction for free cholesterol pool, FSR was taken as the indicator of the fraction of the cholesterol pool that is synthesized over the 24 h period and was calculated as previously reported (20). It is anticipated that 7-DHC and 8-DHC as well as cholesterol are synthesized from the orally administered D2O. Although 7-DHC could be separated from cholesterol, 8-DHC co-elutes with cholesterol using our current method. Accordingly, the FSR measure of cholesterol synthesis also includes some synthesis of 8-DHC.

Plasma sterol analysis

Plasma samples were saponified and extracted in hexane. The concentration of the trimethylsilyl ether derivatives of individual plasma sterols was measured by capillary-column gas chromatography with a CP-Wax 57 column (25m, 0.32mmID; Chrompack-Varian, Walnut Creek CA). Internal standard 5α -cholestane and authentic standard of cholesterol were used for calibration.

Statistical analyses

Data were analyzed using the SAS software (version 8.0; SAS 214 Institute Inc, Cary, NC). Group data are presented as means and standard deviations. A t test was used to compare LO and HI; a paired t test was used to compare HI and HI+ST. Statistical difference was set at P<0.05 for all comparisons.

Results

Twelve SLOS subjects were recruited for the study. Nine subjects were provided with a high cholesterol diet; in one case, crystalline cholesterol was provided instead of egg yolk. A high cholesterol diet with simvastatin, which provided cholesterol in the form of egg yolk, was given to three SLOS subjects. Three SLOS subjects were fed the low cholesterol diet. Liver transaminases and creatine kinase were not elevated in any of the three subjects who received simvastatin with a high cholesterol diet (data not shown). Based on the severity score system, six subjects were classified as mild (<20); five subjects were typical (20-35); and one subject was severe (>35) (15).

Cholesterol fractional synthesis rate, lipid profiles and their responses to cholesterol feeding with and without statin

Nine subjects underwent FSR and sterol profile analysis while consuming a high cholesterol diet. Table 1 presents the individual FSR values, cholesterol, 7-DHC concentrations, cholesterol/(7-DHC+cholesterol) ratios and severity score in SLOS subjects treated with high cholesterol and low cholesterol diets. In comparing LO with HI, FSR was reduced (P<0.001) as a result of high cholesterol feeding (1.46±0.62 %/d and 4.77±0.95 %/d for HI and LO, respectively). The effects of high cholesterol diet and high cholesterol diet with simvastatin on FSR, cholesterol and 7-DHC concentrations are displayed in Figure 1. There was a tendency towards additional FSR reduction in HI+ST compared to HI but this effect was not statistically significant (FSR=1.61± 0.91 %/d and 0.85± 0.44 %/d for HI and HI+ST, respectively; P=0.175; Figure 1(A)). There was, however, a significant decrease in 7-DHC from high cholesterol diet to high cholesterol diet with simvastatin (P=0.01; Figure 1 (C)). Cholesterol concentrations were unchanged in HI+ST, as compared to HI (cholesterol=2.46 ±0.69 mmol/L and 2.77±0.43 mmol/L for HI and HI+ST, respectively; P=0.5; Figure 1 (B)).

Figure 1
Comparing high cholesterol diet group (HI) to high cholesterol diet with simvastatin group (HI+ST). There is tendency towards reduction of (A) cholesterol fractional synthesis rate (FSR) but no change in (B) cholesterol concentrations. There is a significant ...
Table 1
Cholesterol fractional synthesis rate (FSR) in SLOS subjects treated with low cholesterol diet (n=3) and high cholesterol diet (n=9)

Discussion

Our results suggest that a high cholesterol diet reduces whole body in vivo cholesterol synthesis in children with Smith-Lemli-Opitz syndrome as measured by FSR, compared to a low cholesterol diet. The decrease is likely due to inhibition of HMG CoA R, thereby reducing sterol (including cholesterol) synthesis, as well as presumably 7-DHC and 8-DHC synthesis. Moreover, simvastatin added to the high cholesterol diet further decreased circulating 7-DHC concentrations. Therefore, the rationale for considering a high cholesterol diet, with or without simvastatin, as potential therapy is supported. Individuals with SLOS, in whom 7-DHC excess likely contributes to the pathogenesis, may benefit, by reduction of potentially toxic cholesterol precursors: 7-DHC and its isomer 8-DHC.

It has been consistently observed that circulating cholesterol concentrations are increased in SLOS patients after cholesterol supplementation (10-13). It has also been shown that dietary cholesterol can be absorbed by SLOS subjects, although absorption rates may tend to be lower than normal (21). Cholesterol homeostasis is defined by cholesterol absorption, synthesis, and excretion, which together determine blood cholesterol concentration. Supplementing cholesterol in the diet increases circulating cholesterol concentrations (22) directly by absorption of cholesterol from the diet. At the same time, dietary cholesterol depresses sterol (including cholesterol) synthesis via feedback inhibition (23, 24). The effects of interventions such as dietary cholesterol supplementation cannot always be reliably predicted in advance, because of the delicate balance between cholesterol absorption, synthesis, excretion, and uptake from the circulation. This is especially true in disease states affecting cholesterol homeostasis such as SLOS, and this prompted the current study, with the goal of increasing our knowledge of the effects of interventions on sterol homeostasis in SLOS, and evaluation of the deuterium incorporation stable isotope methodology for measuring cholesterol synthesis in SLOS.

To our knowledge, the present study is the first to apply the D2O method to measure cholesterol synthesis from D2O in SLOS, a relatively non-invasive approach for determining cholesterol FSR and the first to directly measure the effect of simvastatin on cholesterol synthesis in SLOS in humans in vivo. We previously measured whole body cholesterol synthesis using the sterol balance technique in SLOS children on a low cholesterol diet (25). However, in children consuming a high cholesterol diet, the large mass of cholesterol excreted renders detection of the small differences between intake and excretion unreliable by that method. Our current results using a different methodology validate the findings demonstrated in our previous study that dietary cholesterol-induced feedback inhibition is intact in SLOS subjects (9).

FSR in children has been measured by the D2O method previously. Indeed, it had been shown previously that FSR ranged from 2%/d to 9%/d and was correlated inversely to dietary cholesterol intake in normal healthy 4 month old infants who did not have SLOS (26). It is apparent that mean FSRs in the present study are lower than those reported above, but the subjects in the earlier published study were younger. Measuring cholesterol synthesis by sterol balance showed that SLOS subjects (aged 0.5 to 13 y) had reduced cholesterol synthesis compared to healthy controls (aged 1-5 y) (25). Future studies with more closely aged matched subjects will clarify if there is a difference in cholesterol synthesis between children with SLOS and healthy children.

There was a tendency towards further FSR reduction when high cholesterol diet with simvastatin was compared to a high cholesterol diet alone, but this did not reach statistical significance. However, 7-DHC concentrations fell significantly with simvastatin administration compared with the high cholesterol diet without a decrease in plasma cholesterol concentrations. Taken together, it is very likely that simvastatin effectively reduced 7-DHC accumulation, by inhibiting HMG CoA R and decreasing flux through the cholesterol synthetic pathway. In addition, expression of DHCR7, was induced by simvastatin in a previous in vitro study (15). In a subsequent animal study, it was further confirmed that expression of DHCR7 increased in response to simvastatin (16). Therefore, it may be that simvastatin upregulates residual DHCR7. In the literature, effects of simvastatin on cholesterol concentrations in SLOS in vivo are inconsistent. Jira et al. reported that circulating cholesterol concentrations were increased almost three-fold after simvastatin was administered to two SLOS subjects for at least 14 months, even without a high cholesterol diet for a part of the study duration (14). In a larger retrospective study, Hass et al. observed a decrease of cholesterol concentrations after simvastatin added to a high cholesterol diet when compared to a high cholesterol diet alone (17). In our current study, although simvastatin with a high cholesterol diet resulted in no further significant change in FSR, plasma cholesterol concentrations were also unchanged as compared to a high cholesterol diet alone. A study with greater subject numbers will be necessary to confirm the effect of administration simvastatin with a high cholesterol diet on cholesterol concentrations and cholesterol synthesis in children with SLOS.

Safety of statin use in SLOS is of paramount importance. Although, there is a paucity of data on safety of statin in children with SLOS, there is a fair amount of published data on safety of statins in children who do not have SLOS. Indeed, statins have been one of the standard medications prescribed to children or adolescents with dyslipedemia (27). A recent comprehensive United States Preventive Services Task Force review of published studies of statins in children revealed a low prevalence of transaminase and creatine kinase elevation and no evidence for significant adverse health effects (28). Specifically, elevations of transaminases and creatine kinase levels with statins have been rarely noted in some studies with children and adolescents, with several studies finding no elevations (29-32). Numerous clinical trials attest to the safety of statins in children and adolescents (28). Furthermore, the US Food and Drug Administration (FDA) has approved the use of some statins in children aged 8 years or older, with familial hypercholesterolemia (27). However, the safety of simvastatin specifically in SLOS subjects was raised in a two-patient study where significant increase in alanine aminotransferase was observed in one subject (33). Furthermore, simvastain treatment may possess potential adverse effects in severely affected SLOS individuals. An in vitro study revealed death of SLOS cell lines with two null mutations in DHCR7 in response to simvastatin treatment (15). In consideration of the potential risks, it is recommended that patients who receive statins undergo routine liver function and creatine kinase tests (27). In the retrospective study of statins in SLOS by Haas et al, six of 39 patients who received additional simvastatin reported side effects, the most consistent of which was sleep problems, which necessitated a reduction or discontinuation of the medication. Many of those subjects had simvastatin re-introduced without difficulty. In the current study, subjects taking simvastatin did not have elevated serum transaminases or creatine kinase levels over the course of the study. This may be due to the fact that none of them had severity score above 35, which was classified to be severe (15). In summary, statins have an excellent safety profile in children who do not have SLOS, but they do have potential toxicity, and the long-term safety in children and in SLOS has not yet been determined, suggesting that widespread use of statins in SLOS outside of the research arena is unwarranted and close monitoring is required.

There were limitations to this study. First, the number of subjects studied was small, so caution is advised in generalizing the results of this study. Second, the mean severity score of the HI group was higher than the mean score in the LO group. We used the severity scoring system that was developed on the basis of anatomical abnormalities (34) and subsequently modified (5, 18). In some studies the severity score was shown to be correlated with biochemical markers (2, 3). Therefore, the differences in severity score between HI and LO could partially account for the lower FSR in HI, as a higher severity score is likely to indicate a more severe enzyme defect. The third limitation of the current study was that 8-DHC could not be separated from cholesterol using our current methodology. Therefore, the FSR presented in the current study may represent both cholesterol and 8-DHC synthesis. However, our earlier sterol balance results showed 7-DHC synthesis represented ~10% of cholesterol synthesis (25). The concentrations of 7-DHC and 8-DHC in plasma are usually similar. Assuming that the synthesis of 7-DHC and 8-DHC are also similar, it is believed that the contribution of 8-DHC to the FSR is likely to be small. More importantly, FSR in the current study represents a measure of flux through the cholesterol synthetic pathway. Therefore, even if our current FSR include 8-DHC synthesis, the overall interpretation of the results is valid, as we are most interested in the effects of interventions on flux through the pathway; we showed decreased flux through the pathway with a high cholesterol diet. Finally, it would be advantageous to be able to measure the FSR of 7-DHC and 8-DHC directly, but technical challenges have so far prevented us from accomplishing that aim.

In conclusion, our findings demonstrate as expected in this cholesterol deficiency syndrome that cholesterol synthesis in children with SLOS is lower than the published values in normal healthy infants, though a direct comparison of FSR in age-matched children using the same methodology in a single study is needed. Furthermore, a high cholesterol diet resulted in the desired reduction of FSR in children with SLOS. A high cholesterol diet with simvastatin may be therapeutic in SLOS since simvastatin decreased plasma 7-DHC with no apparent corresponding drop in cholesterol. A comprehensive understanding of the effects of dietary cholesterol and statins used separately and together, at different doses and for varying durations, will be required in order to optimize future therapeutic strategies in SLOS to determine efficacy. The stable isotope D2O method of determination of FSR can be applied in this patient population and should prove invaluable in determining the effects of these and other therapies in SLOS for testing proposed mechanisms as well as for safety and efficacy monitoring.

Acknowledgements

We would like to thank the staff of the OHSU GCRC (now PCTRC). We also would like to acknowledge Dr. Carrie Phillipi for patient care. We wish to thank the children and their families for participation in this study. We wish to thank numerous health care providers for caring for the subjects who participated in this study, and referring them for these research studies.

Financial Support: Supported by the National Institutes of Health grant no. R01 HL-073980. This publication was made possible with support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research.Category of study: Clinical Study.

Abbreviations

7-DHC
7-dehydrocholesterol
8-DHC
8-dehydrocholesterol
DHCR7
7-dehydrocholesterol reductase
D2O
deuterium oxide
FSR
Cholesterol fractional synthesis rate
GC
gas chromatography
HMG CoA R
hydroxymethylglutaryl coenzyme A reductase
HI
high cholesterol diet group
HI+ST
high cholesterol diet with simvastatin group
LO
low cholesterol diet group
SLOS
Smith-Lemli-Opitz syndrome

References

1. Smith DW, Lemli L, Opitz JM. A newly recognized syndrome of multiple congenital anomalies. J Pediatr. 1964;64:210–217. [PubMed]
2. Cunniff C, Kratz LE, Moser A, Natowicz MR, Kelley RI. Clinical and biochemical spectrum of patients with RSH/Smith-Lemli- Opitz syndrome and abnormal cholesterol metabolism. Am J Med Genet. 1997;68:263–269. [PubMed]
3. Ryan AK, Bartlett K, Clayton P, Eaton S, Mills L, Donnai D, Winter RM, Burn J. Smith-Lemli-Opitz syndrome: a variable clinical and biochemical phenotype. J Med Genet. 1998;35:558–565. [PMC free article] [PubMed]
4. Battaile KP, Steiner RD. Smith-Lemli-Opitz syndrome: the first malformation syndrome associated with defective cholesterol synthesis. Mol Genet Metab. 2000;71:154–162. [PubMed]
5. Kelley RI, Hennekam RC. The Smith-Lemli-Opitz syndrome. J Med Genet. 2000;37:321–335. [PMC free article] [PubMed]
6. Tint GS, Irons M, Elias ER, Batta AK, Frieden R, Chen TS, Salen G. Defective cholesterol biosynthesis associated with the Smith-Lemli- Opitz syndrome. N Engl J Med. 1994;330:107–113. [PubMed]
7. Batta AK, Tint GS, Shefer S, Abuelo D, Salen G. Identification of 8-dehydrocholesterol (cholesta-5,8-dien-3 beta-ol) in patients with Smith-Lemli-Opitz syndrome. J Lipid Res. 1995;36:705–713. [PubMed]
8. Shefer S, Salen G, Batta AK, Honda A, Tint GS, Irons M, Elias ER, Chen TC, Holick MF. Markedly inhibited 7-dehydrocholesterol-delta 7-reductase activity in liver microsomes from Smith-Lemli-Opitz homozygotes. J Clin Invest. 1995;96:1779–1785. [PMC free article] [PubMed]
9. Pappu AS, Steiner RD, Connor SL, Flavell DP, Lin DS, Hatcher L, Illingworth DR, Connor WE. Feedback inhibition of the cholesterol biosynthetic pathway in patients with Smith-Lemli-Opitz syndrome as demonstrated by urinary mevalonate excretion. J Lipid Res. 2002;43:1661–1669. [PubMed]
10. Elias ER, Irons MB, Hurley AD, Tint GS, Salen G. Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS) Am J Med Genet. 1997;68:305–310. [PubMed]
11. Nwokoro NA, Mulvihill JJ. Cholesterol and bile acid replacement therapy in children and adults with Smith-Lemli-Opitz (SLO/RSH) syndrome. Am J Med Genet. 1997;68:315–321. [PubMed]
12. Linck LM, Lin DS, Flavell D, Connor WE, Steiner RD. Cholesterol supplementation with egg yolk increases plasma cholesterol and decreases plasma 7-dehydrocholesterol in smith-lemli-opitz syndrome. Am J Med Genet. 2000;93:360–365. [PubMed]
13. Irons M, Elias ER, Abuelo D, Bull MJ, Greene CL, Johnson VP, Keppen L, Schanen C, Tint GS, Salen G. Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial. Am J Med Genet. 1997;68:311–314. [PubMed]
14. Jira PE, Wevers RA, de Jong J, Rubio-Gozalbo E, Janssen-Zijlstra FS, van Heyst AF, Sengers RC, Smeitink JA. Simvastatin. A new therapeutic approach for Smith-Lemli-Opitz syndrome. J Lipid Res. 2000;41:1339–1346. [PubMed]
15. Wassif CA, Krakowiak PA, Wright BS, Gewandter JS, Sterner AL, Javitt N, Yergey AL, Porter FD. Residual cholesterol synthesis and simvastatin induction of cholesterol synthesis in Smith-Lemli-Opitz syndrome fibroblasts. Mol Genet Metab. 2005;85:96–107. [PubMed]
16. Correa-Cerro LS, Wassif CA, Kratz L, Miller GF, Munasinghe JP, Grinberg A, Fliesler SJ, Porter FD. Development and characterization of a hypomorphic Smith-Lemli-Opitz syndrome mouse model and efficacy of simvastatin therapy. Hum Mol Genet. 2006;15:839–851. [PubMed]
17. Haas D, Garbade SF, Vohwinkel C, Muschol N, Trefz FK, Penzien JM, Zschocke J, Hoffmann GF, Burgard P. Effects of cholesterol and simvastatin treatment in patients with Smith-Lemli-Opitz syndrome (SLOS) J Inherit Metab Dis. 2007;30:375–387. [PubMed]
18. Kratz LE, Kelley RI. Prenatal diagnosis of the RSH/Smith-Lemli-Opitz syndrome. Am J Med Genet. 1999;82:376–381. [PubMed]
19. Vanstone CA, Raeini-Sarjaz M, Parsons WE, Jones PJ. Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. Am J Clin Nutr. 2002;76:1272–1278. [PubMed]
20. Jones PJ, Leitch CA, Li ZC, Connor WE. Human cholesterol synthesis measurement using deuterated water. Theoretical and procedural considerations. Arterioscler Thromb. 1993;13:247–253. [PubMed]
21. Lin DS, Steiner RD, Flavell DP, Connor WE. Intestinal absorption of cholesterol by patients with Smith-Lemli-Opitz syndrome. Pediatr Res. 2005;57:765–770. [PubMed]
22. Fielding CJ, Havel RJ, Todd KM, Yeo KE, Schloetter MC, Weinberg V, Frost PH. Effects of dietary cholesterol and fat saturation on plasma lipoproteins in an ethnically diverse population of healthy young men. J Clin Invest. 1995;95:611–618. [PMC free article] [PubMed]
23. Jones PJ, Pappu AS, Hatcher L, Li ZC, Illingworth DR, Connor WE. Dietary cholesterol feeding suppresses human cholesterol synthesis measured by deuterium incorporation and urinary mevalonic acid levels. Arterioscler Thromb Vasc Biol. 1996;16:1222–1228. [PubMed]
24. Miettinen TA, Kesaniemi YA. Cholesterol absorption: regulation of cholesterol synthesis and elimination and within-population variations of serum cholesterol levels. Am J Clin Nutr. 1989;49:629–635. [PubMed]
25. Steiner RD, Linck LM, Flavell DP, Lin DS, Connor WE. Sterol balance in the Smith-Lemli-Opitz syndrome. Reduction in whole body cholesterol synthesis and normal bile acid production. J Lipid Res. 2000;41:1437–1447. [PubMed]
26. Wong WW, Hachey DL, Insull W, Opekun AR, Klein PD. Effect of dietary cholesterol on cholesterol synthesis in breast-fed and formula-fed infants. J Lipid Res. 1993;34:1403–1411. [PubMed]
27. Daniels SR, Greer FR, Committee on Nutrition Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122:198–208. [PubMed]
28. Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics. 2007;120:e189–e214. [PubMed]
29. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, Sijbrands EJ, Kastelein JJ. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292:331–337. [PubMed]
30. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Amer Coll Cardiol. 2002;40:2117–2121. [PubMed]
31. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;143:74–80. [PubMed]
32. Ducobu J, Brasseur D, Chaudron JM, Deslypere JP, Harvengt C, Muls E, Thomson M. Simvastatin use in children. Lancet. 1992;339:1488. [PubMed]
33. Starck L, Lovgren-Sandblom A, Bjorkhem I. Cholesterol treatment forever? The first Scandinavian trial of cholesterol supplementation in the cholesterol-synthesis defect Smith- Lemli-Opitz syndrome. J Intern Med. 2002;252:314–321. [PubMed]
34. Bialer MG, Penchaszadeh VB, Kahn E, Libes R, Krigsman G, Lesser ML. Female external genitalia and mullerian duct derivatives in a 46,XY infant with the smith-lemli-Opitz syndrome. Am J Med Genet. 1987;28:723–731. [PubMed]